New HIV drug tested in newborns to prevent infection

NCT ID NCT07055451

First seen Oct 31, 2025 · Last updated May 16, 2026 · Updated 28 times

Summary

This study tests a new HIV medicine (B/F/TAF) in full-term newborns who were exposed to HIV but are not infected. The goal is to see if the drug is safe and how the body processes it. Sixteen babies will receive the medicine shortly after birth to help prevent HIV infection.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Durban International Clinical Research Site, Enhancing Care Foundation

    Durban, 4013, South Africa

  • Family Centre for Research with Ubuntu (FAMCRU)

    Cape Town, 7505, South Africa

  • Grady Health System - Ponce de Leon Center

    Atlanta, Georgia, 30308, United States

  • Perinatal HIV Research Unit (PHRU)

    Gauteng, 1864, South Africa

  • Ronald Reagan UCLA Medical Center (inpatient hospital)

    Los Angeles, California, 90095, United States

  • St Jude Children's Research Hospital

    Memphis, Tennessee, 38105, United States

  • WITS RHI Shandukani Research Centre

    Johannesburg, 2001, South Africa

Conditions

Explore the condition pages connected to this study.